Last reviewed · How we verify
YTTRIUM Y 90 IBRITUMOMAB TIUXETAN
At a glance
| Generic name | YTTRIUM Y 90 IBRITUMOMAB TIUXETAN |
|---|---|
| Modality | Monoclonal antibody |
| Phase | FDA-approved |
| First approval | 2002 |
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma (PHASE2)
- Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma (PHASE3)
- S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma (PHASE2)
- A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan (PHASE2)
- Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation (PHASE1, PHASE2)
- A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL) (PHASE3)
- Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas (PHASE2)
- Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YTTRIUM Y 90 IBRITUMOMAB TIUXETAN CI brief — competitive landscape report
- YTTRIUM Y 90 IBRITUMOMAB TIUXETAN updates RSS · CI watch RSS